Bronchoalveolar lavage fluid characteristics of early intermediate and late phases of ARDS. Alterations in leukocytes, proteins, PAF and surfactant components.
about
Disaturated-phosphatidylcholine and surfactant protein-B turnover in human acute lung injury and in control patientsBiosynthesis of oxidized lipid mediators via lipoprotein-associated phospholipase A2 hydrolysis of extracellular cardiolipin induces endothelial toxicityMolecular weight dependence of the depletion attraction and its effects on the competitive adsorption of lung surfactant.Proteomic analysis of pulmonary edema fluid and plasma in patients with acute lung injury.Alterations in the human lung proteome with lipopolysaccharide.Overcoming rapid inactivation of lung surfactant: analogies between competitive adsorption and colloid stability.Elucidating mechanisms of chlorine toxicity: reaction kinetics, thermodynamics, and physiological implications.Inhibition of pulmonary surfactant adsorption by serum and the mechanisms of reversal by hydrophilic polymers: theory.Inactivation of pulmonary surfactant due to serum-inhibited adsorption and reversal by hydrophilic polymers: experimentalEnhanced surfactant adsorption via polymer depletion forces: a simple model for reversing surfactant inhibition in acute respiratory distress syndromeSurfactant disaturated-phosphatidylcholine kinetics in acute respiratory distress syndrome by stable isotopes and a two compartment model.Time-dependent changes in pulmonary surfactant function and composition in acute respiratory distress syndrome due to pneumonia or aspiration.Lipopolysaccharide Cross-Tolerance Delays Platelet-Activating Factor-Induced Sudden Death in Swiss Albino Mice: Involvement of Cyclooxygenase in Cross-ToleranceIncreased phospholipase A2 and lyso-phosphatidylcholine levels are associated with surfactant dysfunction in lung contusion injury in miceCollectins and cationic antimicrobial peptides of the respiratory epithelia.Presumptive acute lung injury following multiple surgeries in a cat.Clinical review: Exogenous surfactant therapy for acute lung injury/acute respiratory distress syndrome--where do we go from here?Mechanisms of polyelectrolyte enhanced surfactant adsorption at the air-water interface.Competitive adsorption: a physical model for lung surfactant inactivation.CD4+CD25+Foxp3+ Tregs resolve experimental lung injury in mice and are present in humans with acute lung injurySurfactant administration in severe inhalation injury: case report.Lung remodeling associated with recovery from acute lung injury.A concentration-dependent mechanism by which serum albumin inactivates replacement lung surfactants.Surfactant phospholipid DPPC downregulates monocyte respiratory burst via modulation of PKC.Bioactive lysophosphatidylcholine 16:0 and 18:0 are elevated in lungs of asthmatic subjects.Stimulated bronchial epithelial cells release bioactive lysophosphatidylcholine 16:0, 18:0, and 18:1.Lower airways inflammation in patients with ARDS measured using endotracheal aspirates: a pilot study.Clearance of surfactant lipids by neutrophils and macrophages isolated from the acutely inflamed lung.The impact of intravenous fat emulsion administration in acute lung injury.Protection afforded by a herbal medicine, Sho-seiryu-to (TJ-19), against oleic acid-induced acute lung injury in guinea-pigs.Pulmonary surfactant disaturated-phosphatidylcholine (DSPC) turnover and pool size in newborn infants with congenital diaphragmatic hernia (CDH).Involvement of the Bufadienolides in the Detection and Therapy of the Acute Respiratory Distress Syndrome.Influence of propofol and volatile anaesthetics on the inflammatory response in the ventilated lung.Are cancer patients adequate candidates for studying apoptosis in septic and ARDS models?
P2860
Q28307833-447E2EAA-0C67-492F-8ECF-6B4C4884D158Q28396065-E97D5C74-C3D2-4B59-886C-BD9965A4B87FQ30484363-33CCCC55-133B-4EF5-B35D-A3ACD5EBCB31Q33197095-7394F0A7-6561-48B2-8385-E9D6A29E0EC5Q33443562-07D0C51A-DE56-47EC-8110-ADF90F21BFC2Q33712598-59D03F42-FF3C-421C-8F5C-D0E415A1C07FQ34119269-E2A58241-DD82-495D-B234-95BDA9BDEAE1Q34351035-A84B4CC7-8B1C-4B0F-B942-D01FDC1D475FQ34351120-0115D3F6-2988-44D3-AECD-8D2FFA3CE2E8Q35220151-14367ADE-7979-4E2E-9666-2AF5FB28B07AQ35674841-EB1B55C4-83C0-44D6-B395-C24AFEEAF5DDQ35945347-687188B2-6B0A-4996-B2DF-4CEF082433F1Q35985649-17A72011-497C-4B24-B216-49735F9CBD65Q36431321-741357D8-C36F-47BA-BDD6-F5064CF77AB7Q36590997-AE1FA9C0-C647-4E71-A6F4-81166E67893BQ36679634-0DD0EC43-26C3-4CFE-952E-929EEAF2680FQ36902581-572FC630-228F-45CE-A059-62DD8F95C421Q37181616-BD9ACFD9-C9E9-44DB-8D0D-0DC37A74E1BAQ37320766-86DF3C2A-C01A-4914-9B19-85256CAA244CQ37363024-C3CECB11-FA6D-44A1-9AF0-EFAE7CDD8681Q38638746-8B35B613-72A5-4909-844B-D89424239E94Q38994633-873AB63F-F543-4B94-97AB-4825E4CEEC02Q40201058-DA04137F-B997-4506-9972-DA369478DEB6Q40463807-2453CCBE-861B-427E-AAB6-F74B294CAECEQ41851858-BAB26DA6-F3BA-409C-8253-437932FBD62DQ41851860-8E6177C2-1338-43B0-9B1A-16F0A95528A7Q42676967-5FD6EF98-D5BF-4EC2-9E8E-291C8BD8CC15Q43855622-13F0B77E-668C-487C-B3BC-E952F541A544Q45157637-1260F256-2216-4804-9B5E-688CDE97E216Q45934047-3263FE73-3B44-4FEB-964B-B546AF5B142AQ47445844-75BC5A6B-8EC7-4E36-9FC9-E74B08A108A1Q47959410-FE764F39-CFB2-4A44-BB3B-C8CE9E70557BQ48260554-35713071-B215-49E7-AF10-20A2F9577417Q52931672-7CBDBADB-CEA5-4431-8BAC-79516A341DA3
P2860
Bronchoalveolar lavage fluid characteristics of early intermediate and late phases of ARDS. Alterations in leukocytes, proteins, PAF and surfactant components.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh-hant
name
Bronchoalveolar lavage fluid c ...... PAF and surfactant components.
@en
Bronchoalveolar lavage fluid c ...... PAF and surfactant components.
@nl
type
label
Bronchoalveolar lavage fluid c ...... PAF and surfactant components.
@en
Bronchoalveolar lavage fluid c ...... PAF and surfactant components.
@nl
prefLabel
Bronchoalveolar lavage fluid c ...... PAF and surfactant components.
@en
Bronchoalveolar lavage fluid c ...... PAF and surfactant components.
@nl
P2093
P2860
P356
P1476
Bronchoalveolar lavage fluid c ...... PAF and surfactant components.
@en
P2093
E I Kitsiouli
I Tsangaris
P2860
P2888
P304
P356
10.1007/S001340050571
P577
1998-04-01T00:00:00Z